Prostate Cancer Clinical Trial
Official title:
Retrospective Study to Evaluate Time to Event and Healthcare Resource Utilization of Prostate Cancer Patients Throughout the Disease Stages, From m0HSPC, m1HSPC, m0CRPC, m1CRPC Until Progression or Death
Verified date | January 2020 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Primary objective of this study is to describe the time in each prostate cancer stage from
non-metastatic Hormone Sensitive Prostate Cancer (m0HSPC), metastatic Hormone Sensitive
Prostate Cancer (m1HSPC), non-metastatic Castrate-Resistant Prostate Cancer (m0CRPC),
metastatic Castrate-Resistant Prostate Cancer (m1CRPC) to progression or death.
The secondary objectives of this study are to describe co-medication at each disease stage,
to describe co-morbidities at each disease stage and to describe the healthcare resource use
and costs associated to each disease stage.
Status | Completed |
Enrollment | 1869 |
Est. completion date | November 28, 2018 |
Est. primary completion date | November 28, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - All patients registered in PPC. Exclusion Criteria: - None. |
Country | Name | City | State |
---|---|---|---|
Sweden | Site SE46001 | Uppsala |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Europe Ltd. |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from entry to exit either by progression or death from prostate cancer stage m0HSPC | M0HSPC as defined by date for start of ADT (Androgen Deprivation Therapy) (bicalutamide or hormone therapy) and no date for metastatic disease. | 11 years | |
Primary | Measure: Time from entry to exit either by progression or death from prostate cancer stage m1HSPC | M1HSPC as defined by date for start of ADT (bicalutamide or hormone therapy) and date for metastatic disease. | 11 years | |
Primary | Time from entry to exit either by progression or death from prostate cancer stage m0CRPC | M0CRPC as defined by date for clinical assessment of CRPC (Castration Resistant Prostate Cancer) or PSA (Prostate-Specific Antigen) progression ((while on GnRH (Gonadotropin-Releasing Hormone) analogues)) and no date for metastases. | 11 years | |
Primary | Time from entry to exit either by progression or death from prostate cancer stage m1CRPC | m1CRPC as defined by date for clinical assessment of CRPC or PSA progression (while on GnRH analogues) and confirmed by date for radiographic progression or initiation of treatment for mCRPC (metastatic castration-resistant prostate cancer). | 11 years | |
Secondary | Co-morbidities at disease stage m0HSPC | The prevalence of different co-morbidities of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-morbidities at disease stage m1HSPC | The prevalence of different co-morbidities of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-morbidities at disease stage m0CRPC | The prevalence of different co-morbidities of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-morbidities at disease stage m1CRPC | The prevalence of different co-morbidities of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-medications at disease stage m0HSPC as recorded in the registries | The prevalence of different co-medications of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-medications at disease stage m1HSPC as recorded in the registries | The prevalence of different co-medications of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-medications at disease stage m0CRPC as recorded in the registries | The prevalence of different co-medications of interest will be summarized for each disease stage. | 11 years | |
Secondary | Co-medications at disease stage m1CRPC as recorded in the registries | The prevalence of different co-medications of interest will be summarized for each disease stage. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by number of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by number of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by number of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by number of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of prostate cancer treatment regimens | Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization in-patient | Healthcare resource utilization and related costs will be assessed by hospitalization in-patient. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization in-patient | Healthcare resource utilization and related costs will be assessed by hospitalization in-patient. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization in-patient | Healthcare resource utilization and related costs will be assessed by hospitalization in-patient. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization in-patient | Healthcare resource utilization and related costs will be assessed by hospitalization in-patient. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization frequency | Healthcare resource utilization and related costs will be assessed by hospitalization frequency. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization frequency | Healthcare resource utilization and related costs will be assessed by hospitalization frequency. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization frequency | Healthcare resource utilization and related costs will be assessed by hospitalization frequency. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization frequency | Healthcare resource utilization and related costs will be assessed by hospitalization frequency. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization duration | Healthcare resource utilization and related costs will be assessed by hospitalization duration. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization duration | Healthcare resource utilization and related costs will be assessed by hospitalization duration. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization duration | Healthcare resource utilization and related costs will be assessed by hospitalization duration. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization duration | Healthcare resource utilization and related costs will be assessed by hospitalization duration. Disease coding is according to International Classification of Diseases 10th Edition (ICD-10). | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of hospital visits | Healthcare resource utilization and related costs will be assessed by type of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of hospital visits | Healthcare resource utilization and related costs will be assessed by type of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of hospital visits | Healthcare resource utilization and related costs will be assessed by type of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of hospital visits | Healthcare resource utilization and related costs will be assessed by type of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of hospital visits | Healthcare resource utilization and related costs will be assessed by frequency of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of hospital visits | Healthcare resource utilization and related costs will be assessed by frequency of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of hospital visits | Healthcare resource utilization and related costs will be assessed by frequency of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of hospital visits | Healthcare resource utilization and related costs will be assessed by frequency of hospital visits. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of imaging examinations | Healthcare resource utilization and related costs will be assessed by type of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of imaging examinations | Healthcare resource utilization and related costs will be assessed by type of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of imaging examinations | Healthcare resource utilization and related costs will be assessed by type of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of imaging examinations | Healthcare resource utilization and related costs will be assessed by type of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of imaging examinations | Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of imaging examinations | Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of imaging examinations | Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of imaging examinations | Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of laboratory tests | Healthcare resource utilization and related costs will be assessed by type of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of laboratory tests | Healthcare resource utilization and related costs will be assessed by type of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of laboratory tests | Healthcare resource utilization and related costs will be assessed by type of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of laboratory tests | Healthcare resource utilization and related costs will be assessed by type of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of laboratory tests | Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of laboratory tests | Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of laboratory tests | Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests. | 11 years | |
Secondary | Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of laboratory tests | Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests. | 11 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |